{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:01:15Z","timestamp":1785398475171,"version":"3.56.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":191,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sam White Legacy","award":["RZ0034"],"award-info":[{"award-number":["RZ0034"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma (GBM) is an aggressive brain tumor characterized by rapid growth and infiltration. New therapies are desperately needed to improve GBM patient outcomes. Intra-tumoral heterogeneity is a common driver of failure for novel GBM treatments, and many preclinical studies rely on cell lines established from the tumor core. As a result, they fail to characterize the infiltrative tumor cells, which remain post-surgery and ultimately drive tumor recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study characterizes the membrane proteome of 3 patient-derived GBM cell lines isolated from the tumor invasive margin (GIN8, GIN28, and GIN31), which is a proxy for residual disease post-surgery. We combined plasma membrane protein analysis with total protein analysis using liquid chromatography-mass spectrometry to uncover therapeutic targets most amenable for drug repurposing. Molecular docking analysis predicted specific binding pockets on the surface of key membrane proteins against which the top 10 approved drug candidates were screened based on their binding energy scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Membrane proteins such as EDIL3, DYSF, ROBO1, SERPINE2, LOXL1, and CD70 were consistently significantly upregulated across GBM cell lines relative to healthy astrocyte controls, indicating potential functional roles in GBM progression. Molecular docking identified nilotinib (targeting LOXL1) and darifenacin (targeting SH3KBP1) as candidate drugs that can bind to identified membrane proteins. Nilotinib and darifenacin produced average IC50 values of 8.45 \u00b5M and 46.77 \u00b5M, respectively, in cell viability assays against GIN cell lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that targeting membrane proteins offers promise for developing effective GBM therapies predicated on the most prognostically relevant intra-tumor region.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag181","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:52:27Z","timestamp":1783597947000},"source":"Crossref","is-referenced-by-count":0,"title":["Membrane proteomic profiling to identify candidate therapy targets for glioblastoma infiltration"],"prefix":"10.1093","volume":"8","author":[{"given":"Harry","family":"Porter","sequence":"first","affiliation":[{"name":"Biodiscovery Institute, School of Medicine, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayley","family":"Mulhall","sequence":"additional","affiliation":[{"name":"Biodiscovery Institute, School of Medicine, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Shah","sequence":"additional","affiliation":[{"name":"Biodiscovery Institute, School of Medicine, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffy Joseph","family":"Vinohar","sequence":"additional","affiliation":[{"name":"Biodiscovery Institute, School of Medicine, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos-Panagiotis","family":"Karadimas","sequence":"additional","affiliation":[{"name":"Biodiscovery Institute, School of Medicine, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaylen","family":"Mistry","sequence":"additional","affiliation":[{"name":"Biodiscovery Institute, School of Medicine, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7953-4239","authenticated-orcid":false,"given":"Simon","family":"Deacon","sequence":"additional","affiliation":[{"name":"Biodiscovery Institute, School of Medicine, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhana","family":"Haque","sequence":"additional","affiliation":[{"name":"The Medical School, College of Health and Science, University of Lincoln , Lincoln,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emyr","family":"Bakker","sequence":"additional","affiliation":[{"name":"The School of Medicine and Dentistry, University of Lancashire , Preston,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Boocock","sequence":"additional","affiliation":[{"name":"John van Geest Cancer Research Centre, The Centre for Systems Health and Integrated Metabolic Research (SHiMR), Nottingham Trent University , Clifton, Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Coveney","sequence":"additional","affiliation":[{"name":"John van Geest Cancer Research Centre, The Centre for Systems Health and Integrated Metabolic Research (SHiMR), Nottingham Trent University , Clifton, Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Layfield","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Queen\u2019s Medical Centre, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruman","family":"Rahman","sequence":"additional","affiliation":[{"name":"Biodiscovery Institute, School of Medicine, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-497X","authenticated-orcid":false,"given":"Phoebe","family":"McCrorie","sequence":"additional","affiliation":[{"name":"Biodiscovery Institute, School of Medicine, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"2026073003265400900_vdag181-B1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/S00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the Central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"2026073003265400900_vdag181-B2","doi-asserted-by":"publisher","first-page":"24535","DOI":"10.1021\/ACSOMEGA.1C02991\/ASSET\/IMAGES\/LARGE\/AO1C02991_0006.JPEG","article-title":"The big picture of glioblastoma malignancy: a meta-analysis of glioblastoma proteomics to identify altered biological pathways","volume":"6","author":"Tribe","year":"2021","journal-title":"ACS Omega"},{"key":"2026073003265400900_vdag181-B3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1011-1344(98)00176-6","article-title":"In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid","volume":"45","author":"Stummer","year":"1998","journal-title":"J Photochem Photobiol B"},{"key":"2026073003265400900_vdag181-B4","doi-asserted-by":"publisher","first-page":"vdaa087","DOI":"10.1093\/NOAJNL\/VDAA087","article-title":"Metabolism-based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential","volume":"2","author":"Smith","year":"2020","journal-title":"Neurooncol Adv"},{"key":"2026073003265400900_vdag181-B5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/S13073-023-01207-1\/FIGURES\/6","article-title":"Spatially resolved transcriptomic profiles reveal unique defining molecular features of infiltrative 5ALA-metabolizing cells associated with glioblastoma recurrence","volume":"15","author":"Andrieux","year":"2023","journal-title":"Genome Med"},{"key":"2026073003265400900_vdag181-B6","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3390\/BRAINSCI13111536","article-title":"Advances in glioblastoma therapy: an update on current approaches","volume":"13","author":"Angom","year":"2023","journal-title":"Brain Sci"},{"key":"2026073003265400900_vdag181-B7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026073003265400900_vdag181-B8","doi-asserted-by":"publisher","first-page":"118237","DOI":"10.1016\/J.BIOPHA.2025.118237","article-title":"The mTOR pathway in gliomas: from molecular insights to targeted therapies","volume":"189","author":"Pournajaf","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"2026073003265400900_vdag181-B9","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3390\/CELLS8080863","article-title":"Current and future trends on diagnosis and prognosis of glioblastoma: from molecular biology to proteomics","volume":"8","author":"Silantyev","year":"2019","journal-title":"Cells"},{"key":"2026073003265400900_vdag181-B10","doi-asserted-by":"publisher","first-page":"593255","DOI":"10.3389\/FIMMU.2021.593255","article-title":"Putting proteomics into immunotherapy for glioblastoma","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"2026073003265400900_vdag181-B11","doi-asserted-by":"publisher","first-page":"vdz029","DOI":"10.1093\/NOAJNL\/VDZ029","article-title":"The invasive proteome of glioblastoma revealed by laser-capture microdissection","volume":"1","author":"Daubon","year":"2019","journal-title":"Neurooncol Adv"},{"key":"2026073003265400900_vdag181-B12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/J.1750-3639.2010.00376.X","article-title":"Glioma pathophysiology: insights emerging from proteomics","volume":"20","author":"Deighton","year":"2010","journal-title":"Brain Pathol"},{"key":"2026073003265400900_vdag181-B13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/J.CELS.2017.03.004","article-title":"A cell-surface membrane protein signature for glioblastoma","volume":"4","author":"Ghosh","year":"2017","journal-title":"Cell Syst"},{"key":"2026073003265400900_vdag181-B14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/J.CCELL.2021.01.006","article-title":"Proteogenomic and metabolomic characterization of human glioblastoma","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"},{"key":"2026073003265400900_vdag181-B15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2026073003265400900_vdag181-B16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/J.CCELL.2021.01.006","article-title":"Proteogenomic and metabolomic characterization of human glioblastoma","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"},{"key":"2026073003265400900_vdag181-B17","doi-asserted-by":"publisher","first-page":"e101239","DOI":"10.1371\/JOURNAL.PONE.0101239","article-title":"Visualizing molecular profiles of glioblastoma with GBM-BioDP","volume":"9","author":"Celiku","year":"2014","journal-title":"PLoS One"},{"key":"2026073003265400900_vdag181-B18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/S12920-023-01593-W\/FIGURES\/4","article-title":"Glioma-BioDP: database for visualization of molecular profiles to improve prognosis of brain cancer","volume":"16","author":"Deng","year":"2023","journal-title":"BMC Med Genomics"},{"key":"2026073003265400900_vdag181-B19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/NEUONC\/NOAB269","article-title":"Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma","volume":"24","author":"Yabo","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026073003265400900_vdag181-B20","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.18632\/ONCOTARGET.3208","article-title":"High expression of N-myc (and STAT) interactor predicts poor prognosis and promotes tumor growth in human glioblastoma","volume":"6","author":"Meng","year":"2014","journal-title":"Oncotarget"},{"key":"2026073003265400900_vdag181-B21","doi-asserted-by":"publisher","first-page":"1353284","DOI":"10.1155\/2020\/1353284","article-title":"L1CAM high expression associates with poor prognosis in glioma but does not correlate with C11orf95-RELA fusion","volume":"2020","author":"Zeng","year":"2020","journal-title":"Biomed Res Int"},{"key":"2026073003265400900_vdag181-B22","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/SCIENCE.1260419","article-title":"Proteomics. tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"2026073003265400900_vdag181-B23","author":"Human Protein Atlas"},{"key":"2026073003265400900_vdag181-B24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/ANA.22036","article-title":"Residual tumor cells are unique cellular targets in glioblastoma","volume":"68","author":"Glas","year":"2010","journal-title":"Ann Neurol"},{"key":"2026073003265400900_vdag181-B25","doi-asserted-by":"publisher","first-page":"vdae012","DOI":"10.1093\/NOAJNL\/VDAE012","article-title":"Potential roles for efferocytosis in glioblastoma immune evasion","volume":"6","author":"Lorimer","year":"2024","journal-title":"Neurooncol Adv"},{"key":"2026073003265400900_vdag181-B26","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1042\/BCJ20200339","article-title":"Novel pyrano 1,3 oxazine based ligand inhibits the epigenetic reader hBRD2 in glioblastoma","volume":"477","author":"Deshmukh","year":"2020","journal-title":"Biochem J"},{"key":"2026073003265400900_vdag181-B27","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.2147\/OTT.S115974","article-title":"Positive expression of KIF20A indicates poor prognosis of glioma patients","volume":"9","author":"Duan","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2026073003265400900_vdag181-B28","doi-asserted-by":"publisher","first-page":"901951","DOI":"10.3389\/FONC.2022.901951","article-title":"Metabolic rewiring in glioblastoma cancer: EGFR, IDH and Beyond","volume":"12","author":"El Khayari","year":"2022","journal-title":"Front Oncol"},{"key":"2026073003265400900_vdag181-B29","doi-asserted-by":"publisher","first-page":"583984","DOI":"10.3389\/FONC.2020.583984","article-title":"SH3KBP1 promotes glioblastoma tumorigenesis by activating EGFR signaling","volume":"10","author":"Song","year":"2021","journal-title":"Front Oncol"},{"key":"2026073003265400900_vdag181-B30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3892\/MMR.2020.11650","article-title":"High expression of CIN85 promotes proliferation and invasion of human esophageal squamous cell carcinoma","volume":"23","author":"Hua","year":"2021","journal-title":"Mol Med Rep"},{"key":"2026073003265400900_vdag181-B31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/J.SURONC.2016.09.003","article-title":"Slit2 and Robo1 expression as biomarkers for assessing prognosis in brain glioma patients","volume":"25","author":"Liu","year":"2016","journal-title":"Surg Oncol"},{"key":"2026073003265400900_vdag181-B32","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1038\/s41591-024-03138-9","article-title":"Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells","volume":"30","author":"Chokshi","year":"2024","journal-title":"Nat Med"},{"key":"2026073003265400900_vdag181-B33","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s42003-024-06712-6","article-title":"CD58 defines regulatory macrophages within the tumor microenvironment","volume":"7","author":"Wu","year":"2024","journal-title":"Commun Biol"},{"key":"2026073003265400900_vdag181-B34","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1136\/JITC-2021-003289","article-title":"CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment","volume":"10","author":"Seyfrid","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026073003265400900_vdag181-B35","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1186\/S12885-023-11637-0","article-title":"Knockdown of SLC39A14 inhibits glioma progression by promoting erastin-induced ferroptosis SLC39A14 knockdown inhibits glioma progression","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer 2023 Cancer"},{"key":"2026073003265400900_vdag181-B36","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1126\/SCIENCE.AAF2666","article-title":"An anatomic transcriptional atlas of human glioblastoma","volume":"360","author":"Puchalski","year":"2018","journal-title":"Science"},{"key":"2026073003265400900_vdag181-B37","doi-asserted-by":"publisher","first-page":"100206","DOI":"10.1016\/J.MCPRO.2022.100206","article-title":"Simple but efficacious enrichment of integral membrane proteins and their interactions for in-depth membrane proteomics","volume":"21","author":"Kongpracha","year":"2022","journal-title":"Mol Cell Proteomics"},{"key":"2026073003265400900_vdag181-B38","doi-asserted-by":"publisher","first-page":"101637","DOI":"10.1016\/J.JCMGH.2025.101637","article-title":"Targeting LOXL1-expressing hepatic stellate cell inhibits fibrogenesis and sinusoid angiogenesis via LOXL1\/RUNX1\/VEGFA axis during progression of liver fibrosis","volume":"20","author":"Yan","year":"2026","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2026073003265400900_vdag181-B39","doi-asserted-by":"publisher","first-page":"12270","DOI":"10.3390\/IJMS232012270","article-title":"Lysyl oxidase family proteins: prospective therapeutic targets in cancer","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026073003265400900_vdag181-B40","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/J.1365-2184.2011.00761.X","article-title":"Serine palmitoyltransferase inhibitor myriocin induces growth inhibition of B16F10 melanoma cells through G2\/M phase arrest","volume":"44","author":"Lee","year":"2011","journal-title":"Cell Prolif"},{"key":"2026073003265400900_vdag181-B41","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1093\/ONCOLO\/OYAD216.024","article-title":"Phase 1\/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies","volume":"28","author":"Jonasch","year":"2023","journal-title":"Oncologist"},{"key":"2026073003265400900_vdag181-B42","doi-asserted-by":"publisher","first-page":"705260","DOI":"10.3389\/FIMMU.2021.705260\/BIBTEX","article-title":"CD58 immunobiology at a glance","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"2026073003265400900_vdag181-B43","doi-asserted-by":"publisher","first-page":"6819","DOI":"10.3390\/MOLECULES28196819\/S1","article-title":"Virtual screening and binding analysis of potential CD58 inhibitors in colorectal cancer (CRC)","volume":"28","author":"Guo","year":"2023","journal-title":"Molecules"},{"key":"2026073003265400900_vdag181-B44","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/1476-4598-9-271\/FIGURES\/7","article-title":"The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis","volume":"9","author":"Bergeron","year":"2010","journal-title":"Mol Cancer"},{"key":"2026073003265400900_vdag181-B45","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.3390\/IJMS23073706","article-title":"Small-Molecule RAS inhibitors as anticancer agents: discovery, development, and mechanistic studies","volume":"23","author":"Shetu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026073003265400900_vdag181-B46","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/JM020017N","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J Med Chem"},{"key":"2026073003265400900_vdag181-B47","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"64","author":"Lipinski","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"2026073003265400900_vdag181-B48","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1038\/s41418-020-0558-4","article-title":"LOXL1 confers antiapoptosis and promotes gliomagenesis through stabilizing BAG2","volume":"27","author":"Yu","year":"2020","journal-title":"Cell Death Differ"},{"key":"2026073003265400900_vdag181-B49","doi-asserted-by":"publisher","first-page":"840241","DOI":"10.3389\/FONC.2022.840241\/FULL","article-title":"Identification of synergistic drug combinations to target KRAS-Driven chemoradioresistant cancers utilizing tumoroid models of colorectal adenocarcinoma and recurrent glioblastoma","volume":"12","author":"Gupta","year":"2022","journal-title":"Front Oncol"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag181\/68757406\/vdag181.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag181\/68757406\/vdag181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag181\/68757406\/vdag181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:26:57Z","timestamp":1785396417000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag181\/8732296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag181","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag181"}}